Mydosone (prednisolone + sulphacetamide): Uses, Dosage & Side Effects

What it's for (Indications)

This ophthalmic combination product, exemplified by Orbaleph, is specifically formulated for the treatment of inflammatory ocular conditions in which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Conditions typically treated include chronic anterior uveitis, steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
It is also indicated for ocular injury from chemical, radiation, or thermal burns, or penetration of foreign bodies when the inherent hazard of steroid use in these conditions is accepted.
The antibacterial component, sulfacetamide, provides coverage against susceptible organisms, preventing or treating bacterial superinfection in these inflammatory states.

Dosage Information

Type	Guideline
Standard	The typical dosage involves instilling one or two drops into the conjunctival sac of the affected eye(s) every four to six hours. During the initial 24 to 48 hours, the dosage may be increased to one or two drops every two hours, as deemed necessary by the treating physician based on the severity of the condition. Treatment should not be abruptly discontinued, and the frequency should be gradually tapered as the condition improves. It is crucial to follow the prescribing physician's instructions precisely regarding dosage, frequency, and duration of therapy, and not to self-adjust the regimen. Prolonged use without medical supervision can lead to serious ocular complications, necessitating careful patient adherence.

Type

Guideline

Standard

The typical dosage involves instilling one or two drops into the conjunctival sac of the affected eye(s) every four to six hours. During the initial 24 to 48 hours, the dosage may be increased to one or two drops every two hours, as deemed necessary by the treating physician based on the severity of the condition. Treatment should not be abruptly discontinued, and the frequency should be gradually tapered as the condition improves. It is crucial to follow the prescribing physician's instructions precisely regarding dosage, frequency, and duration of therapy, and not to self-adjust the regimen. Prolonged use without medical supervision can lead to serious ocular complications, necessitating careful patient adherence.

Safety & Warnings

Common Side Effects

Common ocular side effects include transient burning, stinging, irritation, blurred vision, and conjunctival hyperemia immediately after instillation.
Prolonged use, particularly of the corticosteroid component, is associated with more severe risks, including increased intraocular pressure (IOP) leading to glaucoma with potential optic nerve damage, visual acuity defects, and field defects.
Posterior subcapsular cataract formation is another significant long-term risk, especially in children.
There is also an increased susceptibility to secondary ocular infections (bacterial, fungal, viral) and delayed wound healing following ocular surgery or injury.
Allergic reactions, including rare but severe sulfonamide reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis, can occur, though less commonly with topical ophthalmic application.

Serious Warnings

Black Box Warning: While a formal FDA Black Box Warning for topical ophthalmic prednisolone-sulfacetamide combination products is not universally established, healthcare professionals must be acutely aware of the significant and potentially severe risks associated with their use. **Serious Ocular Complications and Hypersensitivity Reactions** necessitate extreme caution. Prolonged use of the corticosteroid component can lead to substantial increases in intraocular pressure (IOP), potentially resulting in glaucoma with optic nerve damage, irreversible visual field loss, and the formation of posterior subcapsular cataracts, which may require surgical intervention. Corticosteroids can also mask, enhance, or activate serious secondary ocular infections, including those caused by herpes simplex virus, fungi, and resistant bacteria, delaying diagnosis and appropriate treatment of severe infectious conditions and potentially leading to permanent vision impairment or loss. Furthermore, the sulfacetamide component carries a risk of severe and sometimes fatal hypersensitivity reactions, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and agranulocytosis, even with topical administration. Patients should be closely monitored for any signs of these severe systemic or ocular reactions, and the medication must be discontinued immediately if suspected. Given these severe potential risks, this product should only be used under close ophthalmologic supervision and when the potential benefits unequivocally outweigh the considerable and well-documented risks.
Use of this product requires careful monitoring due to several serious potential risks.
Prolonged use of corticosteroids can lead to elevated intraocular pressure and subsequent glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.
Patients receiving prolonged treatment should have their intraocular pressure checked routinely.
The use of corticosteroids may mask, activate, or exacerbate secondary ocular infections caused by fungi, viruses (especially herpes simplex), or bacteria, and delay healing of corneal abrasions.
Acute purulent untreated infections of the eye may be masked or enhanced by the presence of corticosteroid medication.
Hypersensitivity reactions to the sulfonamide component, including serious and sometimes fatal reactions like Stevens-Johnson syndrome, toxic epidermal necrolysis, or anaphylaxis, have been reported; discontinue use immediately if signs of hypersensitivity appear, including skin rash, fever, or blood dyscrasias.

How it Works (Mechanism of Action)

The therapeutic effect of this combination product is derived from the distinct mechanisms of its two active components. Prednisolone, a potent corticosteroid, exerts its anti-inflammatory effects by inhibiting the release of arachidonic acid, thereby blocking the synthesis of prostaglandins and leukotrienes. It also stabilizes lysosomal membranes, inhibits phagocytosis, and reduces the extravasation of fluids, all contributing to the suppression of inflammation and immune responses. Sulfacetamide, a sulfonamide antibiotic, works by competitively inhibiting para-aminobenzoic acid (PABA), an essential precursor for bacterial synthesis of folic acid. This inhibition disrupts the bacterial metabolic pathway for nucleotide synthesis, thereby impeding bacterial growth and replication, rendering it bacteriostatic against a broad spectrum of Gram-positive and Gram-negative bacteria susceptible to sulfonamides, preventing their proliferation in the ocular environment.